The use of autologous stem-cell transplantation in the treatment of follicular lymphoma remains controversial ... from two randomized trials, GELF-86 and GELF-94. The inclusion of rituximab ...

Follicular Lymphoma International Prognostic Index (FLIPI) and tumor burden, as judged by the GELF score, are each in use for risk stratification. A period of observation at diagnosis may be ...

Those that grow and spread slowly are described as ‘indolent’, one of the most common types of which is follicular lymphoma. About one-fifth of new cases of non-Hodgkin lymphoma are diagnosed ...

The study entitled: Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to ...

18 The Follicular Lymphoma International Prognostic Index (FLIPI) is a commonly used clinical tool that uses 5 factors to assess prognosis for FL: aged >60 years, Ann Arbor stage III to IV ...

CR 85% Previously transformed follicular lymphoma: ORR 100%; CR 73% ≥1 GELF criteria: ORR 97%; CR 75% High-risk FLIPI score: ORR 96%; CR 67% Response was durable: Among the responders ...

What’s the next step for this patient with a 4-year history of low-grade follicular lymphoma and who now has worsening lymphadenopathy and needs a nap at the end of every work day? Share on ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.